Saturday 2 June 2012

Oral Transmucosal Drug Delivery - Business Review Europe

NEW YORK, May 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Oral Transmucosal Drug Delivery

http://www.reportlinker.com/p0870772/Oral-Transmucosal-Drug-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

In their search for alternative delivery methods that will enhance compliance and improve safety, drug developers and researchers are discovering that the permeability of mucous membranes provides a convenient route for the systemic delivery of new and existing therapeutic drugs. Transmucosal delivery offers the potential for once daily dosing of oral drugs and avoids the effects of first pass metabolism. On the provider side, the development of alternative methods of drug administration has improved the ability of physicians to manage specific problems. Practitioners now recognize the rapid onset, relative reliability, and the general lack of patient discomfort when drugs are administered by the transmucosal route. We expect this market to experience healthy growth through 2015 as buccal technology is applied to existing drugs and as transmucosal formulations become an important route of administration for an increasing number of new NCEs. Growth in this sector will also be driven by the pressure to extend market protection for numerous existing drugs with soon-to-expire patents.

Highlights

? Analyzes and evaluates oral transmucosal drug delivery technology platforms and their impact on the market

? Analyzes oral transmucosal drug products and pipeline product candidates

? Provides assessments of key oral transmucosal drug therapeutic categories

? Provides market data and forecasts to 2016

? Profiles market participants, their product development activities and strategies

Executive Summary

Executive Summary

Drug Delivery Market Dynamics

Evolution in Drug Development

Market and Demand Drivers

Shifting Patient Demographics

The Impact of Generics

Managed Care Initiatives

Competitive Landscape

Competing Transmucosal Delivery Technologies

Oral Sprays

Buccal Films and Tablets

Sublingual Films and Wafers

Commercial Transmucosal Formulation Platforms

Adversa

BEMA

Bioadhesive Delivery System

Corplex

FluidCrystal

Intravail

Lauriad

OraDisc

OraVescent

RapidMist

Transmucosal Film

Oral Transmucosal Drug Technology Factors

Absorption

Bioavailability

Adhesion

Pharmacokinetics

FDA-Approved Oral Transmucosal Products

Asenapine

Buprenorphine (3 products)

Ergotamine

Fentanyl (8 products)

Hydergine

Isosorbide dinitrate (2 products)

Miconazole

Nitroglycerin (3 Products)

Ondansetron

Testosterone

Zolpidem (3 products)

Zuplenz

Important Pipeline Product Candidates

Agomelatine

ALKS 5461

Buprenorphine

Buprehorphine

Buprenorphine

Cannabinoid

Desmopressin

Fentanyl

Fentanyl

Granisetron

Insulin

Ramelteon

Sufentanil

Sumatriptan

Zolpidem

Zolpidem

Market Assessments & Forecasts

Addiction

Anti-infectives

Cardiology

Diabetes

Immunology

Infectious Disease

Neurology

Oncology

Pain Management

Sexual Health

Vaccines

Market Factors

Formulations and Proprietary Platforms

Government Regulations

Patent Expiration and Rx-to-OTC Switching

Market Participant Profiles

To order this report:

Drug Delivery Technology Industry: Oral Transmucosal Drug Delivery

More ?Market Research Report

Check our ?Industry Analysis and Insights

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

josh hamilton nba playoffs rosario dawson young jeezy world wildlife fund gsa keith olbermann

No comments:

Post a Comment